Xenon Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenon Pharmaceuticals Inc. on January 10, 2020, covering events occurring on January 8 and January 9, 2020. The Company is incorporated in Canada and its common shares trade on The Nasdaq Global Market under the symbol "XENE".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The filing reports the following material changes to the Board of Directors:
- Appointment: Dr. Clarissa Desjardins was appointed as a director, effective January 13, 2020.
- Resignation: Dr. Richard Scheller submitted his resignation from the Board, effective January 14, 2020. He stated no disagreement with the Company's operations or policies.
- Committee Changes: Dr. Desjardins replaced Dr. Scheller on the Compensation Committee, effective January 13, 2020.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies were disclosed in this report. Dr. Desjardins will receive compensation under the standard plan for non-employee directors, including an initial stock option grant.
Investor Verification Checklist
- Verify the effective dates of Dr. Desjardins' appointment and Dr. Scheller's resignation (January 13 and 14, 2020, respectively).
- Review the Company's definitive proxy statement on Schedule 14A (filed April 29, 2019) for details on the Director Compensation Policy.
- Confirm the updated composition of the Audit, Compensation, and Nominating and Corporate Governance Committees.